A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

Key facts

Study ID

NCT06730750

Run by

Bristol-Myers Squibb

People needed

360

Starts

2025-02-12

Expected to finish

2029-12-09

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
• CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:
• i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated).
• NSCLC: Part 2A-NSCLC/GC, 2L+ NSCLC:
• i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease.
• ii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.
• GC: Part 2A-NSCLC/GC, 2L+ GC: i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy).
• ii) ECOG performance status of 0 or 1.

You may not qualify if…

• History of anaphylactic reactions to irinotecan and/or bevacizumab.
• Previously received therapy targeting CEACAM5.
• Grade ≥3 ILD/pneumonitis.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Tasman Oncology Research — Southport, Queensland, Australia (enrolling)
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
• Local Institution - 0007 — Los Angeles, California, United States
• Local Institution - 0017 — Grand Rapids, Michigan, United States
• Local Institution - 0004 — Hackensack, New Jersey, United States
• Local Institution - 0006 — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.